Key Insights

Highlights

Success Rate

50% trial completion

Treatment Research

14 treatments under study, led by Trastuzumab

Research Leaders

8 sponsors active, led by Jiangsu HengRui Medicine Co., Ltd.

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 62/100

Termination Rate

20.0%

2 terminated out of 10 trials

Success Rate

50.0%

-36.6% vs benchmark

Late-Stage Pipeline

20%

2 trials in Phase 3/4

Results Transparency

50%

1 of 2 completed with results

Key Signals

1 with results50% success

Data Visualizations

Phase Distribution

10Total
Phase 1 (1)
Phase 1/2 (2)
Phase 2 (5)
Phase 3 (2)

Trial Status

Unknown5
Terminated2
Completed2
Active Not Recruiting1

Trial Success Rate

50.0%

Benchmark: 86.6%

Based on 2 completed trials

Clinical Trials (10)

Showing 10 of 10 trials
NCT04829604Phase 2Active Not RecruitingPrimary

ARX788 in HER2-positive, Metastatic Breast Cancer Subjects (ACE-Breast-03)

NCT03691051Phase 2UnknownPrimary

A Study of Pyrotinib Plus Capecitabine in Patients With Brain Metastases From HER2-positive Metastatic Breast Cancer

NCT04681287Phase 2UnknownPrimary

Exploratory Study of Advanced Breast Cancer in HER2 Positive Patients With Failure of Multi-line Therapy Treated by Combination of Inetetamab (Cipterbin) + PD-1 Inhibitor Combined With Utidelone.

NCT02973737Phase 3UnknownPrimary

A Study of Pyrotinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer

NCT00810017Phase 2TerminatedPrimary

Phase 2 Study of Trastuzumab and Etoposide for Her2 Positive Breast Cancer

NCT04398108Phase 1CompletedPrimary

A Study to Evaluate the Pharmacokinetics of Margetuximab in Chinese Patients With HER2+ MBC

NCT03080805Phase 3UnknownPrimary

Pyrotinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer. (PHOEBE)

NCT02422199Phase 1/2UnknownPrimary

A Study of Pyrotinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+Metastatic Breast Cancer Who Have Prior Received Anthracyclin, Taxane or Trastuzumab

NCT01495884Phase 1/2TerminatedPrimary

The Myocet/Lapatinib Study. ICORG 10-03, V5

NCT00146042Phase 2CompletedPrimary

UMCC 9901: Phase II Study of Tailored-Dose Docetaxel + Trastuzumab in Her-2 Positive Metastatic Breast Cancer

Showing all 10 trials

Research Network

Common Treatments

  • Trastuzumab2
  • Pyrotinib Plus Capecitabine2
  • Capecitabine2
  • Pyrotinib2
  • Lapatinib Tyverb1

Active Sponsors

  • Jiangsu HengRui Medicine Co., Ltd.3
  • Genentech, Inc.2
  • Henan Cancer Hospital2
  • Cancer Trials Ireland1
  • University of Michigan Rogel Cancer Center1

Top Investigators

Activity Timeline